3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lymphoma, Large B-Cell, Diffuse
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Prostatic Neoplasms
7
Lymphoma
5
Burkitt Lymphoma
5
Neoplasms
4
Leukemia, Biphenotypic, Acute
4
Ovarian Neoplasms
3
Lymphoma, Follicular
3
Hodgkin Disease
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Metastatic Castration-resistant Prostate Cancer
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Leukemia
2
Endometrial Neoplasms
2
Down Syndrome
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Myasthenia Gravis
1
Lymphoma, T-Cell, Peripheral
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Immunoblastic Lymphadenopathy
1
Heart Failure
1
Enteropathy-Associated T-Cell Lymphoma
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
enzalutamide
3
darolutamide
2
abiraterone
2
pembrolizumab
1
bicalutamide
1
abemaciclib
1
Prednisolone
1
Goserelin
1
Docetaxel
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bulbo-Spinal Atrophy, X-Linked
×
Prednisolone
×
1 year
×
Clear all
NCT06764485
2026-05-06
rechARge
Celgene
Phase 3
Recruiting
960 enrolled